WJPPS Citation

Submit Manuscript

Search

News & Updation

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: New Impact Factor 2026
  • WJPPS Impact Factor has been Increased to 8.485 for Year 2026.

  • WJPPS: OCTOBER ISSUE PUBLISHED
  • OCTOBER 2026 Issue has been successfully launched on 1 OCTOBER 2026.

Abstract

LONG-ACTING INJECTABLES DRUG DELIVERY LINKING RELEASE MECHANISMS, PLATFORM DESIGN AND THERAPEUTIC APPLICATIONS

*Miss. Priya Ramchandra Injal, Miss. Siddhi Sadashiv Mandhare, Miss. Jaipa Zakir Nayakwadi, Miss. Shreya Dipak Deshmukh, Smt. S. S. Chavan

ABSTRACT

Long-acting injectables (LAIs) are innovative drug-delivery systems allowing for prolonged controlled release of a drug after a single administration. By decreasing the dosing frequency, long-acting injectable can have a positive impact on treatment compliance, patient convenience, and drug exposure while minimising the peak–trough fluctuations. This review provides an overview of the different formulation approaches used to develop LAIs, including microspheres, Nano crystal suspensions, oil-based depots, in situ forming depots, implants, hydrogels, lyotropic liquid crystalline systems, polymer-lipid hybrids, and modified protein and peptide therapeutics. The review highlights the main advantages and limitations of LAIs, such as patient adherence and consistent drug exposure, while also discussing injection site reactions, prolonged drug exposure, challenges of flexible dose adjustment, manufacturing complexity, and cost. Storage requirements will be discussed. The clinical applications in schizophrenia and bipolar disorder, HIV treatment and prevention, opioid use disorder, growth hormone deficiency, and diabetes. Ophthalmic diseases will be highlighted together with the marketed products in each therapeutic area. Finally, emerging technologies, patient-friendly LAI approaches, biomaterials, artificial intelligence, predictive modelling, and personalised medicine are discussed. In conclusion, LAIs are an important class of drug delivery systems that can have a significant impact on optimal and sustained drug exposure while decreasing the treatment burden on the patient. The complexity of the different formulation approaches and the need for clinical development expertise are still major hurdles that industry is currently trying to address by developing new approaches and manufacturing processes.

Keywords: Long-acting injectable [LAI], Drug release mechanisms, Controlled drug release, PLGA microspheres, Depot formulations.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More